157 related articles for article (PubMed ID: 29254168)
1. LC-MS-based metabolomics revealed SLC25A22 as an essential regulator of aspartate-derived amino acids and polyamines in
Li X; Chung ACK; Li S; Wu L; Xu J; Yu J; Wong C; Cai Z
Oncotarget; 2017 Nov; 8(60):101333-101344. PubMed ID: 29254168
[TBL] [Abstract][Full Text] [Related]
2. SLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells With KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate.
Wong CC; Qian Y; Li X; Xu J; Kang W; Tong JH; To KF; Jin Y; Li W; Chen H; Go MY; Wu JL; Cheng KW; Ng SS; Sung JJ; Cai Z; Yu J
Gastroenterology; 2016 Nov; 151(5):945-960.e6. PubMed ID: 27451147
[TBL] [Abstract][Full Text] [Related]
3. In Colorectal Cancer Cells With Mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA Demethylation to Increase WNT Signaling, Stemness, and Drug Resistance.
Wong CC; Xu J; Bian X; Wu JL; Kang W; Qian Y; Li W; Chen H; Gou H; Liu D; Yat Luk ST; Zhou Q; Ji F; Chan LS; Shirasawa S; Sung JJ; Yu J
Gastroenterology; 2020 Dec; 159(6):2163-2180.e6. PubMed ID: 32814111
[TBL] [Abstract][Full Text] [Related]
4. Targeting of SLC25A22 boosts the immunotherapeutic response in KRAS-mutant colorectal cancer.
Zhou Q; Peng Y; Ji F; Chen H; Kang W; Chan LS; Gou H; Lin Y; Huang P; Chen D; Wei Q; Su H; Liang C; Zhang X; Yu J; Wong CC
Nat Commun; 2023 Aug; 14(1):4677. PubMed ID: 37542037
[TBL] [Abstract][Full Text] [Related]
5. Determination of amino acids in colon cancer cells by using UHPLC-MS/MS and [U-
Li X; Wong CC; Tang Z; Wu J; Li S; Qian Y; Xu J; Yang Z; Shen Y; Yu J; Cai Z
Talanta; 2017 Jan; 162():285-292. PubMed ID: 27837831
[TBL] [Abstract][Full Text] [Related]
6. Alteration of intracellular metabolome in osteosarcoma stem cells revealed by liquid chromatography-tandem mass spectrometry.
Zhong Z; Mao S; Lin H; Li H; Lin J; Lin JM
Talanta; 2019 Nov; 204():6-12. PubMed ID: 31357340
[TBL] [Abstract][Full Text] [Related]
7. Metabolic Alterations Caused by KRAS Mutations in Colorectal Cancer Contribute to Cell Adaptation to Glutamine Depletion by Upregulation of Asparagine Synthetase.
Toda K; Kawada K; Iwamoto M; Inamoto S; Sasazuki T; Shirasawa S; Hasegawa S; Sakai Y
Neoplasia; 2016 Nov; 18(11):654-665. PubMed ID: 27764698
[TBL] [Abstract][Full Text] [Related]
8. Quantitative metabolomics for investigating the value of polyamines in the early diagnosis and therapy of colorectal cancer.
Liu R; Lin X; Li Z; Li Q; Bi K
Oncotarget; 2018 Jan; 9(4):4583-4592. PubMed ID: 29435126
[TBL] [Abstract][Full Text] [Related]
9. Mass spectrometry-based metabolomics approach and in vitro assays revealed promising role of 2,3-dihydroquinazolin-4(1H)-one derivatives against colorectal cancer cell lines.
Dahabiyeh LA; Hudaib F; Hourani W; Darwish W; Abu-Irmaileh B; Deb PK; Venugopala KN; Mohanlall V; Chandrashekharappa S; Abu-Dahab R; Semreen MH; Bustanji Y
Eur J Pharm Sci; 2023 Mar; 182():106378. PubMed ID: 36638899
[TBL] [Abstract][Full Text] [Related]
10. Metabolomics study on the antitumor effect of marine natural compound flexibilide in HCT-116 colon cancer cell line.
Gao D; Wang Y; Xie W; Yang T; Jiang Y; Guo Y; Guan J; Liu H
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Mar; 1014():17-23. PubMed ID: 26859520
[TBL] [Abstract][Full Text] [Related]
11. Deciphering the metabolic profile and anti-colorectal cancer mechanism of Capilliposide A using ultra performance liquid chromatography mass spectrometry combined with non-targeted metabolomics studies.
Li W; Zhang X; Feng Y; Han H; Cai J; Zhao H; Li S; Tian J; Zhu W
J Pharm Biomed Anal; 2023 Sep; 234():115548. PubMed ID: 37390605
[TBL] [Abstract][Full Text] [Related]
12. Metabolomics of adherent mammalian cells by capillary electrophoresis-mass spectrometry: HT-29 cells as case study.
Ibáñez C; Simó C; Valdés A; Campone L; Piccinelli AL; García-Cañas V; Cifuentes A
J Pharm Biomed Anal; 2015 Jun; 110():83-92. PubMed ID: 25818703
[TBL] [Abstract][Full Text] [Related]
13. Urinary metabonomic study on colorectal cancer.
Qiu Y; Cai G; Su M; Chen T; Liu Y; Xu Y; Ni Y; Zhao A; Cai S; Xu LX; Jia W
J Proteome Res; 2010 Mar; 9(3):1627-34. PubMed ID: 20121166
[TBL] [Abstract][Full Text] [Related]
14. Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool.
Brown DG; Rao S; Weir TL; O'Malia J; Bazan M; Brown RJ; Ryan EP
Cancer Metab; 2016; 4():11. PubMed ID: 27275383
[TBL] [Abstract][Full Text] [Related]
15. Polarity-Tuning Derivatization-LC-MS Approach for Probing Global Carboxyl-Containing Metabolites in Colorectal Cancer.
Bian X; Li N; Tan B; Sun B; Guo MQ; Huang G; Fu L; Hsiao WLW; Liu L; Wu JL
Anal Chem; 2018 Oct; 90(19):11210-11215. PubMed ID: 30193063
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic approach to breast cancer patients based on target metabolomics in saliva by liquid chromatography with tandem mass spectrometry.
Takayama T; Tsutsui H; Shimizu I; Toyama T; Yoshimoto N; Endo Y; Inoue K; Todoroki K; Min JZ; Mizuno H; Toyo'oka T
Clin Chim Acta; 2016 Jan; 452():18-26. PubMed ID: 26523874
[TBL] [Abstract][Full Text] [Related]
17. Metabolomics-A Promising Approach to Pituitary Adenomas.
Pînzariu O; Georgescu B; Georgescu CE
Front Endocrinol (Lausanne); 2018; 9():814. PubMed ID: 30705668
[No Abstract] [Full Text] [Related]
18. Metabolic signatures of esophageal cancer: NMR-based metabolomics and UHPLC-based focused metabolomics of blood serum.
Zhang X; Xu L; Shen J; Cao B; Cheng T; Zhao T; Liu X; Zhang H
Biochim Biophys Acta; 2013 Aug; 1832(8):1207-16. PubMed ID: 23524237
[TBL] [Abstract][Full Text] [Related]
19. Pseudotargeted metabolomics method and its application in serum biomarker discovery for hepatocellular carcinoma based on ultra high-performance liquid chromatography/triple quadrupole mass spectrometry.
Chen S; Kong H; Lu X; Li Y; Yin P; Zeng Z; Xu G
Anal Chem; 2013 Sep; 85(17):8326-33. PubMed ID: 23889541
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
